Type 2 diabetes is a global epidemic despite current medical treatments. Many patients are not responsive to medications, and patients with obesity are hesitant about bariatric surgery. Studies investigating the metabolic effects of Roux-en-Y gastric bypass have increasingly demonstrated that the duodenum plays a key role in the pathophysiology of type 2 diabetes. This has led to the emergence of small bowel endoscopic therapies for type 2 diabetes. These therapies include procedures such as duodenal ablation, luminal liners, endoscopic bypasses, and endoscopic injections.
Patel et al. (Tue,) studied this question.